POLISCOPE
Back to feed
HR6112FEDERALIN_COMMITTEE
High Impact

New Reporting Rules for Drug Ingredients and Supply Chain Security

Original title: Further Strengthening America’s Supply Chain and National Security Act

December 17, 2024

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

Where This Stands

Introduced
Committee
Floor Vote
Passed
Signed

Currently IN_COMMITTEE. The next step in the legislative lifecycle is Floor Vote.

Version history

Only one version on file - nothing to compare yet. As later stages (committee substitute, engrossed, enrolled) are captured, the redline appears here.

View official text →

The Frame

What this does

This legislation changes how the U.S. tracks the origin of medicine ingredients, potentially impacting which foreign suppliers pharmaceutical companies use and how the Department of Defense assesses risks to the military's drug supply.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Pharmaceutical manufacturers

They must submit annual reports detailing the sources and percentages of all active and inactive ingredients used in their products.

Department of Defense

They will receive annual reports on drug ingredient sources to evaluate supply chain risks for the Armed Forces.

Drug and device manufacturing facilities

They are subject to new risk-factor considerations during FDA inspections, including their location and history of illicit exports.

What changed

Current stage: IN_COMMITTEE.

What's next

Floor Vote.

Background

  • The bill is part of ongoing legislative efforts to reduce U.S. reliance on foreign-manufactured medical supplies, a concern that gained prominence during the COVID-19 pandemic. context

Summary

This bill requires pharmaceutical companies to disclose the specific sources and percentages of all ingredients used in their drugs to the federal government. It also updates trade rules to ensure active pharmaceutical ingredients are tracked by their country of origin and mandates that the FDA consider foreign adversary influence when inspecting drug manufacturing facilities.

Key Facts

You don't have to trust us. Each fact below is taken straight from the official document - click any one to see the exact passage, highlighted in the original.

Why It Matters

This legislation changes how the U.S. tracks the origin of medicine ingredients, potentially impacting which foreign suppliers pharmaceutical companies use and how the Department of Defense assesses risks to the military's drug supply.

Frequently Asked Questions

Will my drug company reveal my personal medical information?
No. The bill requires reporting on the sources of drug ingredients, not patient data. Furthermore, the government is required to publish this information in an aggregate form that does not disclose proprietary business information.
How will this affect the military?
The Department of Defense will receive the reported ingredient data to better understand the military's reliance on foreign manufacturers for essential drugs.

News Coverage

Sponsors

Analysis Score

0–100
  • Significance80
    How much this matters to a regular citizen
  • Controversy40
    Intensity of disagreement among stakeholders
  • Entertainment10
    Compellingness for a non-policy-wonk reader
  • Buzz30
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record